Abstract
Peter B Bach and colleagues call for an end to contradictory regulatory standards in the US that allow drug manufacturers to boost profits by producing single dose vials containing quantities that increase leftover drug
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents / economics*
-
Antineoplastic Agents / therapeutic use
-
Cost Control / economics*
-
Drug Costs
-
Drug Packaging / economics*
-
European Union
-
Humans
-
Neoplasms / drug therapy
-
Neoplasms / economics*
-
Prescription Drugs / economics
-
Prescription Fees
-
United States
Substances
-
Antineoplastic Agents
-
Prescription Drugs